44 completed, 27 recruiting, 17 unknown, 11 terminated. 59 Phase 2, 28 Phase 1, 15 Not applicable, 11 Phase 3, 3 Phase 4.
Follow Prostate Cancer Metastatic: new trials by email Literature Review of Prostate Cancer Metastatic trials Research Report on Prostate Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| A Phase 1/2 Trial of ADI-212 in mCRPC ADI-212, Fludarabine, Cyclophosphamide - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Not yet recruiting | Adicet Therapeutics | 12 | 2026-09-01 | 2026-09-10 |
| 18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients Prostate Cancer, Prostate Cancer Metastatic | Not yet recruiting | Assiut University | 59 | 2026-05-01 | 2026-03-20 | |
| Geriatric Assessment and Technology Evaluation in Prostate Cancer Questionnaires - Prostate Cancer, Prostate Cancer Metastatic | Recruiting | University of Chicago | 120 | 2026-04-01 | 2025-06-08 | |
| AI-based Prediction of Prostate Cancer Metastasis Using Biopsy Pathology Artificial Intelligence-Based Pathology Analysis - Prostate Cancer Metastatic | Enrolling by invitation | Xiangya Hospital of Central South University | 3000 | 2026-01-08 | 2026-06-22 | |
| A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 humanized monoclonal anti-FGFR1 antibody OM-RCA-01 - Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Kidney Cancer Research Bureau | 58 | 2025-12-02 | 2026-01-21 |
| A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC CC-38, Pembrolizumab, Cyclophosphamid - Metastatic Colorectal Cancer, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | CuraCell TX AB | 12 | 2025-11-13 | 2026-06-22 |
| Exercise in Prostate Cancer Exercise Intervention - Prostate Cancer Metastatic, Prostate Cancer | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2025-10-16 | 2026-10-29 |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Abivertinib, Abiraterone - Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 100 | 2025-09-01 | 2024-03-18 |
| Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria Prostate Cancer, Prostate Cancer (Diagnosis) | Recruiting | Société Algérienne de Formation et Recherche en Oncologie | 2000 | 2025-07-21 | 2026-04-17 | |
| 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer Fasting, Ketone Supplementation - Prostate Cancer, Prostate Cancer Metastatic | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 40 | 2025-06-03 | 2026-06-30 |
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 Administering Lutetium-177-PSMA-617 (PLUVICTO) - Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis | Phase 2 | Recruiting | Ebrahim S Delpassand | 30 | 2025-05-23 | 2025-05-15 |
| PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN) PSMA PET/CT scan - PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1300 | 2025-04-02 | 2026-02-20 | |
| Castrate Resistant Prostate Cancer Enhertu Therapy Enhertu - Prostate Cancer Metastatic, Prostate Cancer | Phase 2 | Recruiting | Washington D.C. Veterans Affairs Medical Center | 60 | 2025-03-05 | 2026-04-13 |
| Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA Parametric acquisition - Prostate Cancer Metastatic | Not applicable | Recruiting | Centre Henri Becquerel | 60 | 2025-03-05 | 2026-01-02 |
| Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer 177Lu-PSMA-617 - Prostate Cancer Metastatic | Completed | Central Hospital, Nancy, France | 80 | 2024-12-31 | 2026-06-25 | |
| The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer FAPI PET/CT - Prostate Cancer, Prostate Cancer Metastatic | Not applicable | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2024-12-01 | 2024-10-09 |
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) 177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic | Phase 3 | Recruiting | UNICANCER | 500 | 2024-09-12 | 2024-12-20 |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic | Phase 3 | Recruiting | University College, London | 3360 | 2024-06-11 | 2025-09-26 |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study Radical prostatectomy, Prostate irradiation, Surgical metastasectomy - Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone | Not yet recruiting | Medical University of Vienna | 500 | 2024-05-31 | 2024-05-28 |
Showing 20 of 124. Sign in to see all of them.
Prostatic Neoplasms (62) · Neoplasm Metastasis (13) · Breast Neoplasms (5) · Neoplasms (5) · Disease (3) · Motor Activity (3) · Prostatic Diseases (3) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Glioblastoma (2) · Melanoma (2) · Neoplastic Cells, Circulating (2) · Neuroendocrine Tumors (2)
Neoplasms (69) · Neoplasms by Site (68) · Male Urogenital Diseases (65) · Urogenital Diseases (65) · Genital Diseases (64) · Genital Diseases, Male (62) · Urogenital Neoplasms (62) · Genital Neoplasms, Male (61) · Prostatic Diseases (61) · Pathological Conditions, Signs and Symptoms (20) · Pathologic Processes (19) · Neoplastic Processes (16) · Neoplasms by Histologic Type (7) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
enzalutamide (12) · Prednisone (11) · Abiraterone Acetate (9) · Docetaxel (9) · Androgen Antagonists (8) · Radiosurgery (8) · cabazitaxel (7) · gallium 68 PSMA-11 (7) · darolutamide (6) · abiraterone (5) · Pluvicto (4) · Standard of Care (4) · pembrolizumab (4) · Magnetic Resonance Spectroscopy (3) · Radiotherapy (3)
Sanofi (5) · The Netherlands Cancer Institute (4) · Dana Mathews (3) · DexTech Medical AB (3) · Fudan University (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University Hospital, Ghent (3) · University of Chicago (3) · British Columbia Cancer Agency (2) · Imperial College London (2) · Memorial Sloan Kettering Cancer Center (2) · Orion Corporation, Orion Pharma (2) · The European Uro-Oncology Group (2) · UNICANCER (2) · University of Michigan Rogel Cancer Center (2)
United States (56) · France (14) · Spain (14) · Canada (13) · Netherlands (13) · United Kingdom (13) · China (11) · Germany (11) · Belgium (9) · Italy (9) · Denmark (8) · Poland (8) · Sweden (7) · Australia (6) · Finland (6)
Orhan K Oz, MD, PhD (3) · Anders R Holmberg, CEO (2) · Andre Bergman, MD, PhD (2) · Susanne Osanto, MD PhD (2) · Abi Vainstein-Haras, MD (1) · Albert Font Pous, Dr (1) · Ana Molina, MD (1) · Anders Holmberg, MD (1) · Andrea Farolfi (1) · Andrew Armstrong, MD (1) · Andrew Dorr, MD (1)
PMID 38421252, PMID 42020286, PMID 25001524, PMID 25639506, PMID 28632486, PMID 30301829, PMID 30817251, PMID 31428443, PMID 31566937, PMID 32398040, PMID 32926841, PMID 33084183, PMID 33386290, PMID 33463373, PMID 34274136, PMID 34326126, PMID 34376554, PMID 34450475, PMID 34794989, PMID 34961659, PMID 35276694, PMID 35363301, PMID 35715340, PMID 35963650, PMID 36480560, PMID 36503429, PMID 36682096, PMID 36717150, PMID 36753698, PMID 37058234, PMID 37821242, PMID 37883073, PMID 37889298, PMID 37922910, PMID 38320513, PMID 38622987, PMID 38758815, PMID 38769643, PMID 38885246, PMID 39008067, PMID 39496182, PMID 39670468, PMID 39915126, PMID 40138611, PMID 40306965, PMID 40339593, PMID 40451460, PMID 40619537, PMID 40638235, PMID 40906325
2016 (2), 2014 (1), 2017 (1), 2023 (1), 2025 (1)